CTI BioPharma and Servier announce exclusive license and collaboration agreement
CTI BioPharma and Servier jointly announced an exclusive license and collaboration agreement to develop and commercialize PIXUVRI® (pixantrone) in a transaction valued at up to $133.5 million, if all milestones are achieved. September 17, 2014